logo
Science seek to tap amazing healing powers of the mouth's interior

Science seek to tap amazing healing powers of the mouth's interior

UPI16 hours ago
1 of 2 | The amazing ability of the mouth's lining to quickly heal itself without scarring is likely due to a specific cellular action that could be applied to skin wounds sustained elsewhere on the body, according to a study released Wednesday. File Photo by Molly Riley/UPI | License Photo
ST. PAUL, Minn., July 2 (UPI) -- The cellular action that enables the mouth's interior lining to heal quicky and without scarring has always been a mystery but a new study suggests it may be linked to a specific "signaling pathway."
That new knowledge is raising hopes the mouth lining's healing powers could be applied to other skin wounds, which take far longer to heal and often leave permanent, unsightly scars, according to a preclinical study published Wednesday by Cedars-Sinai Medical Center and University of California-San Francisco researchers.
The study on mice provides evidence that the "Gas6/AXL" protein/enzyme signaling pathway is likely responsible for the mouth's amazing ability to heal itself completely from even deep bite wounds within a matter of days with no leftover scarring, the authors wrote in the journal Science Translational Medicine.
Known as the oral mucosa, the mouth's interior lining heals fast and cleanly, even though it is continuously exposed to different types of microbes, abrasion from foods, motion and tension. This unique regenerative capacity is made possible by specialized gene programs activated during injury, but just how those mechanisms work has been unknown.
In the study reported Wednesday, a research team led by Dr. Ophir Klein, executive vice dean of Children's Health at Cedars-Sinai and executive director of Cedars-Sinai Guerin Children's in Los Angeles, found that by manipulating levels of the AXL enzyme they could affect how wounds healed.
For instance, if they inhibited AXL in mice, the healing of oral mucosa wounds worsened, making them more like skin wounds. Conversely, when they stimulated AXL in facial skin wounds, they healed more efficiently and with reduced scarring, much like the oral mucosa.
Boosting the levels of AXL suppresses the expression of another protein called Focal Adhesion Kinase, or FAK, which plays a significant role in scar formation during wound healing.
Should future research validate the benefits for humans, the new knowledge could aid in developing new therapies to heal skin wounds with reduced scarring, Klein said.
"We are actively thinking about harnessing AXL-driven repair in both the mouth and the skin, and perhaps in other tissues as well," he told UPI in emailed comments. "One application that comes to mind is to improve healing and reduce scarring in the skin for burn victims or those with other cutaneous disorders.
"Another is that there are a number of diseases of the mouth, many of them autoimmune, in which severe oral ulcers form and heal poorly or not at all. These are different from canker sores, also known as aphthous ulcers, which many people get and which typically heal on their own; the more severe ulcers are difficult to treat and cause very significant illnesses, and we currently do not have good therapies for them."
A related direction for research could focus on "obtaining a deeper understanding of the effects of AXL signaling on scarring and regeneration at a molecular level, in terms of other components of the signaling pathways," Klein added.
"It will also be interesting to explore the role of this pathway in other tissues and organs, and in the context of distinct injuries and perturbations --for example, physical cuts vs heat burns vs irradiation versus chemical insults."
Meanwhile, a pair of recent animal studies led by the University of Arizona in Tucson similarly have shown that the use of FAK inhibitors can make skin grafts look more like healthy skin and produce less scarring, raising hopes for a potential new treatment for survivors of blast wounds, burns and other major injuries.
Kellen Chen, an assistant research professor in the university's Department of Surgery and lead author of those papers, said the current Cedars-Sinai study appears to add to a mounting list of evidence that "FAK acts as a central mediator of scarring in the oral mucosa gives additional credence to the importance of this factor." Chen was not involved with the new study.
"A better understanding of how the oral mucosa heals without scarring through the FAK pathway will allow us to better develop therapies to target FAK for healing in the future," he told UPI.
Chen said his team has the funding to pursue Food and Drug Administration approval for a FAK inhibitor, or FAKI, hydrogel therapy and expects to conduct human trials soon.
The growing evidence that wound healing can be accelerated at the cellular level "could have strong clinical implications for the treatment of severe injuries for humans and animals, especially because there are zero FDA-approved treatments that reduce scar formation," he added.
"Patients with severe injuries or burns can suffer a lifetime of pain and disfigurement from scarring. The potential to heal burn injuries with regeneration, rather than scarring, would dramatically change the lives of these patients."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Philadelphia native cycling across the country to raise money for lung cancer patients
Philadelphia native cycling across the country to raise money for lung cancer patients

CBS News

time8 hours ago

  • CBS News

Philadelphia native cycling across the country to raise money for lung cancer patients

Twenty-year-old Jack Owens made a pit stop Wednesday at Valley Forge National Park in Pennsylvania. The Philadelphia cyclist is riding coast to coast to help lung cancer patients. "It's been a long journey," Owens said. He started the 48-day trip May 20 in San Francisco and will end in Ocean City. He's aiming to raise $100,000 for lung cancer patients. "It's something that affects everybody," he said. "It's the leading cancer killer among every demographic in every state." Owens' grandmother died from lung cancer, which inspired her son, John Matthews, to start a charity called Ride Hard Breathe Easy. Matthews is Owens' uncle. "When Mom was sick, I just said I would do something," Matthews said. "I had no idea I was going to ride my bike across the country." Matthews, who's doing part of the ride with Owens, completed his cross-country trek in 2017. "It's amazing," Matthews said. "It's really inspiring." The money that Owens raises on this ride will help lung cancer patients with getting to doctor's appointments and paying for food and utility bills. "They just need someone to give them a hand and we're fortunate to do it," Matthews said. Owens, who went to St. Joe's Prep, is now a junior at Notre Dame, and he's dedicating part of his summer break to the family mission of helping patients. On their way to the shore where the 3,600 mile journey will end on July 6, they'll stop at some hospitals that treat the patients they help, like Fox Chase Cancer Center.

Gilmour Space again delays launch of Australia's first orbital rocket
Gilmour Space again delays launch of Australia's first orbital rocket

UPI

time11 hours ago

  • UPI

Gilmour Space again delays launch of Australia's first orbital rocket

July 2 (UPI) -- The Australian aerospace firm Gilmour Space has again delayed the launch of its Eris 1 rocket, the country's first orbital rocket. Gilmour Space said Wednesday that it was standing down from a planned launch of what would be the first test flight of the rocket. "We've made the tough call to postpone this week's launch," the company said in a statement. It said the pause would give them a longer and more flexible launch window, and the team "a chance to rest after an intense few weeks of testing and prep." The company said the new launch window would depend on weather conditions and approval from regulators but that the next launch window is likely no earlier than July 16. On Monday, the company had said that the rocket was on the launch pad but that the winds weren't favorable for a launch. Gilmour Space had previously sought to launch the rocket on May 15 but encountered problems during routine shutdown procedures. At the time, the rocket's payload fairing -- a protective cone for the payload at the nose of the rocket -- unexpectedly separated from the launch vehicle. The cause of the incident went unexplained until May 30 when Gilmour Space revealed that the separation was caused by an unexpected power surge traced to electrical feedback during the vehicle's shutdown sequence. "No, it wasn't a cockatoo," the company said at the time. The company was founded by brothers Adam and James Gilmour in 2015 and now has more than 200 employees.

Study: Statins could prevent tens of thousands of heart attacks, strokes
Study: Statins could prevent tens of thousands of heart attacks, strokes

UPI

time13 hours ago

  • UPI

Study: Statins could prevent tens of thousands of heart attacks, strokes

More than 39,000 deaths, nearly 100,000 non-fatal heart attacks and up to 65,000 strokes in the U.S. could be prevented if people eligible for statins and other cholesterol-lowering drugs were taking them, researchers reported Monday. Adobe stock/HealthDay July 2 (UPI) -- Tens of thousands of people suffer needless heart attacks and strokes every year because they aren't taking cholesterol-lowering drugs, a new study says. More than 39,000 deaths, nearly 100,000 non-fatal heart attacks and up to 65,000 strokes in the U.S. could be prevented if people eligible for statins and other cholesterol-lowering drugs were taking them, researchers reported Monday in the Journal of General Internal Medicine. Nearly half of Americans (47%) who have never had a heart attack or stroke are eligible to take statins under U.S. guidelines, researchers found. But fewer than a quarter (23%) of them have been prescribed the life-saving drugs, results show. A substantial number of heart attack or stroke survivors also aren't taking the drugs, even though all are eligible for them under U.S. guidelines, researchers said. "These results add to a growing body of evidence that there are important shortcomings in the quality of care for common and costly chronic diseases such as high cholesterol, and that addressing those shortcomings would yield major public health benefits," lead researcher Dr. Caleb Alexander, a professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health, said in a news release. For the study, researchers analyzed data from nearly 5,000 U.S. adults between 40 and 75 years of age who took part in an annual U.S. Centers for Disease Control and Prevention health survey between 2013 and 2020. The survey included data on the people's "bad" LDL cholesterol levels and their overall heart health risk profile. Researchers used that info to determine whether they'd be eligible to take cholesterol-lowering drugs under current guidelines. Even people who had suffered a prior heart attack and stroke -- and thus are at higher risk for a follow-up event -- aren't always prescribed statins, researchers found. Only about two-thirds (68%) are taking statins, even though all are eligible for the drugs under the guidelines, results show. Along with warding off heart attacks and strokes, properly prescribed statins also could prevent every year nearly 88,000 heart bypass surgeries and procedures to reopen blocked or clogged arteries, researchers estimated. If everyone eligible for statins took them, researchers estimate that average LDL cholesterol levels would drop sharply and the risk of heart attack or stroke would fall by up to 27%. Preventing heart attacks and strokes through cholesterol-lowering drugs also could save more than $30 billion in annual medical costs for the U.S., researchers estimate. "Several factors account for the gaps that we document," Alexander said. "They include differences in clinician training, patient preferences, barriers to accessing care, financial incentives that don't always support best practices, and the difficulty of putting clinical guidelines into practice in busy, real-world settings." Better patient education and improved screening methods could make sure the right people are taking the statins they need, researchers said. "High cholesterol is an important chronic health condition that silently claims far too many lives -there are millions of people walking around with this condition that don't even know they have it, and then when it is recognized it too often goes undertreated," senior author Dr. Seth Martin, a professor of cardiology at the Johns Hopkins University School of Medicine, said in a news release. "Evidence-based action is critical to close the gap and prevent devastating cardiovascular events," he said. More information Harvard Medical School has more on statins. Copyright © 2025 HealthDay. All rights reserved.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store